AI-generated summary
The authors ran a randomized, double-blind, placebo-controlled trial of six weeks of transcranial photobiomodulation in people with persistent concussion symptoms. After adjusting for prior concussions, they report no significant difference between the treatment and placebo groups at three or six weeks. They suggest further work is needed on dose or timing.
- Participants
- 48
- Who or what was studied
- Patients aged 11 years or older receiving care for persistent postconcussion symptoms
- Limits stated in the abstract
- The treatment group reported more previous concussions despite randomization, and the abstract does not state the wavelengths used.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on ovid.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Placebo-controlled, Primary outcome, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.